Carbatol CR-200 Tablet

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

CARBAMAZEPINE

Boleh didapati daripada:

LABORATORIES TORRENT (MALAYSIA) SDN. BHD.

INN (Nama Antarabangsa):

CARBAMAZEPINE

Unit dalam pakej:

100Tablet Tablets; 10 Tablet Tablets; 30 Tablet Tablets

Dikeluarkan oleh:

TORRENT PHARMACEUTICALS LTD

Ciri produk

PRODUCT NAME
:
ITEM / PACK
:
DESIGN STYLE
:
CODE
:
DIMENSIONS (MM)
:
ART WORK SIZE
:
DATE
:
Reviewed By
NO. OF COLORS: 1
COUNTRY : Malaysia
Front/Back
Carbatol CR
Insert
S/S
180 x 350
xxxxxxxxx-5253
Black
25-05-2021
PANTONE SHADE NOS.:
ACTIVITIES
DEPARTMENT
NAME
SIGNATURE
DATE
Prepared By
PKG.DEV
PKG.DEV
LOCATION :
Chhatral
QUALITY
Approved By
complete urinalysis and BUN determinations at baseline and
periodically
thereafter are recommended.
Due to its mild anticholinergic activity, carbamazepine should be used
with
caution in patients with increased intraocular pressure and patients
should
be warned regarding the possible hazards.
Carbamazepine may also cause activation of latent psychosis and, in
elderly patients, of confusion or agitation.
Carbamazepines have been associated with decreased platelet or white
blood cell counts occuring occasionally to frequently and rarely with
agranulocytosis. The patients and their relatives should be informed
about
the early signs and symptoms indicative of potential hematological
problem
and symptoms of dermatological or hepatic reactions. The physician
should
be consulted immediately on occurrence of events like fever, sore
throat,
rash, mouth ulcers, easy bruising, petechial or purpuric hemorrhage.
The patient showing a definite low or decreased platelet count during
treatment should be closely monitored and treatment with carbamazepine
should
be
discontinued
if
any
evidence
of
significant
bone
marrow
depression appears and in case of leucopenia which is severe,
progressive
or accompanied by fever or sore throat.
Carbamazepine should be used with caution in patients with history of
liver
disease and in elderly patients and liver function tests should be
performed
before starting the carbamazepine therapy. Therapy should be
discontinued
immediately in case of acute liver disease or aggravated liver
dysfunction.
However, it should not be withdrawn in cases of abnormal liver
function
tests
resulting
from
the
hepatic
enzyme
inhibition
property
of
carbamazepine.
Mild skin react